Company profile
Cambium Oncology company profile
Cambium Oncology LLC is a pre-clinical start-up focused on developing and commercializing new immuno-oncology therapeutics that target a novel checkpoint pathway. The company has licensed a patented technology from Emory University to use inhibitory peptides designed against immuno-suppressive vasoactive intestinal peptide (VIP) to cause both in vitro and in vivo activation and proliferation of T cells. Administration of VIP-antagonist peptides trigger a robust cytotoxic T-cell mediated immune response in tumor-bearing animals that resulted in reduction of tumor size and increase in survival time.
Business identity
- Website
- https://cambiumoncology.com/
- Contact email
- [email protected]
- Phone number
- 404-693-7796
- Operating status
- Active
- Company type
- For Profit
- Founded
- 2018-01-01
Headquarters
- Headquarters
- Johnson, Arkansas, United States
- Postal code
- 30306
- Country code
- US
- Continent
- North America